Okayama University


Okayama University Medical Research Updates (OU-MRU) Vol.28

August 30, 2016

Source: Okayama University (JAPAN), Public Relations and Information Strategy
For immediate release: 30 August 2016
Okayama University research: Viral-based therapy for bone cancer

(Okayama, 30 August) Scientists at Okayama University develop a viral-based technique specific to bone cancer that enhances patients’ sensitivity to chemotherapy.

Certain cancers, including osteosarcoma (bone cancer), are unresponsive to chemotherapy, making disease prognosis very poor. Osteosarcoma is a rare but severe form of cancer that predominantly affects the growing bones in children and adolescents. The cancerous tissue in osteosarcoma is resistant to chemotherapy, but the precise molecular mechanisms involved are unclear. The search is on to find a way of enhancing the chemo-sensitivity of patients, so that they are more responsive to treatment.

Now, Toshiyoshi Fujiwara and co-workers at Okayama University, Japan, have developed a new combined therapy which uses the properties of a virus to disrupt osteosarcoma cancer cells and enable chemotherapy agents to destroy them. Their findings may transform treatment of bone cancer and other chemo-resistant cancers in future.

One possible target for improving chemo-sensitivity is the BCL2 protein family; these proteins are overexpressed in cancer tissues and aid in the progression of the disease. One such protein is MCL1, whose role is to limit cancer cell death in tumors. The researchers focused on finding a way of downregulating MCL1 in osteosarcoma in the hope that it might encourage chemo-sensitivity.

To do this, Fujiwara’s team used their newly-engineered ‘telomerase-specific ocolytic adenovirus OBP-301 (telomelysin)’, which they had previously shown could reduce the growth of stomach tumors. They created a combined therapy using OBP-301 with chemotherapy agents. The researchers found that OBP-301 activated microRNA-29, which in turn worked to downregulate MCL1. MCL1 knockdown resulted in high levels of cancer cell death in osteosarcoma tumors, weakening the tumors and leaving them open to the effects of chemotherapy.

As the researchers state in their paper in Nature Scientific Reports; “Virus-mediated telomerase-specific targeting of MCL1 expression offers a promising strategy to improve the clinical benefits of conventional chemotherapy in osteosarcoma patients.”

Background Adenoviruses
Adenoviruses are common, stable and hardy viruses that have been increasingly used as vectors (or ‘carriers’) for vaccines and in gene therapy for targeting multiple illnesses. The viruses are capable of infecting multiple cell types, and can therefore be used to target specific diseased cells such as cancerous tissue. The adenoviruses have a relatively simple genome, meaning scientists can modify the genome easily to carry out specific jobs in targeted tissues.

In this study, Toshiyoshi Fujiwara and his team adapted an adenovirus (labelled OBP-301) to target and downregulate the MCL1 protein in osteosarcoma. They created a combined therapy using OBP-301 with chemotherapy agents, which they trialed on both in vitro tissue samples and in vivo conditions (using a xenograft model). They found that the therapy activated microRNA molecules (including miR-29) which worked to knockdown MCL1, resulting in higher levels of cancer cell death in tumors. This then made the tumors more vulnerable to the effects of chemotherapy.

Crucially, the therapy specifically targets tumors and does not impact on surrounding healthy cells.

Future work
Further investigations are needed into patient tolerance of the combined therapy, and whether or not the treatment is safe, efficient and effective in humans.

Shuhei Osaki, Hiroshi Tazawa, Joe Hasei, Yasuaki Yamakawa, Toshinori Omori,Kazuhisa Sugiu, Tadashi Komatsubara, Tomohiro Fujiwara, Tsuyoshi Sasaki, Toshiyuki Kunisada, Aki Yoshida, Yasuo Urata, Shunsuke Kagawa, Toshifumi Ozaki, and Toshiyoshi Fujiwara. Ablation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas. Scientific Reports, 6, Article number: 28953 (2016)
DOI : 10.1038/srep28953

Reference (OU-MRU) : Professor Fujiwara’s team
Vol.1:Innovative non-invasive ‘liquid biopsy’ method to capture circulating tumor cells from blood samples for genetic testing
Vol.7:Anticancer virus solution provides an alternative to surgery
Vol.21:Combined gene transduction and light therapy targets gastric cancer

Correspondence to
Professor Toshiyoshi Fujiwara, M.D., Ph.D.
Department of Gastroenterological Surgery, Okayama
University Graduate School of Medicine, Dentistry and
Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku,
Okayama 700-8558, Japan
e-mail : toshi_f( a )md.okayama-u.ac.jp
For inquiries, please contact us by replacing (a) with the @ mark.

Further information
Okayama University
1-1-1 Tsushima-naka , Kita-ku , Okayama 700-8530, Japan
Public Relations and Information Strategy
E-mail: www-adm (a) adm.okayama-u.ac.jp
For inquiries, please contact us by replacing (a) with the @ mark.

Website: //www.okayama-u.ac.jp/index_e.html
Okayama Univ. e-Bulletin: //www.okayama-u.ac.jp/user/kouhou/ebulletin/
Okayama Univ. e-Bulletin (PDF Issues): //www.okayama-u.ac.jp/user/kouhou/ebulletin/
About Okayama University (You Tube): https://www.youtube.com/watch?v=iDL1coqPRYI
Okayama University Image Movie (You Tube): https://www.youtube.com/watch?v=_WnbJVk2elA

Okayama University Medical Research Updates (OU-MRU)
Vol.1:Innovative non-invasive ‘liquid biopsy’ method to capture circulating tumor cells from blood samples for genetic testingVol.2:Ensuring a cool recovery from cardiac arrestVol.3:Organ regeneration research leaps forwardVol.4:Cardiac mechanosensitive integratorVol.5:Cell injections get to the heart of congenital defectsVol.6:Fourth key molecule identified in bone developmentVol.7:Anticancer virus solution provides an alternative to surgeryVol.8:Light-responsive dye stimulates sight in genetically blind patientsVol.9:Diabetes drug helps towards immunity against cancerVol.10:Enzyme-inhibitors treat drug-resistant epilepsyVol.11:Compound-protein combination shows promise for arthritis treatmentVol.12:Molecular features of the circadian clock system in fruit fliesVol.13:Peptide directs artificial tissue growthVol.14:Simplified boron compound may treat brain tumoursVol.15:Metamaterial absorbers for infrared inspection technologiesVol.16:Epigenetics research traces how crickets restore lost limbsVol.17:Cell research shows pathway for suppressing hepatitis B virusVol.18:Therapeutic protein targets liver diseaseVol.19:Study links signalling protein to osteoarthritisVol.20:Lack of enzyme promotes fatty liver disease in thin patientsVol.21:Combined gene transduction and light therapy targets gastric cancerVol.22:Medical supportive device for hemodialysis catheter punctureVol.23:Development of low cost oral inactivated vaccines for dysenteryVol.24:Sticky molecules to tackle obesity and diabetesVol.25:Self-administered aroma foot massage may reduce symptoms of anxietyVol.26:Protein for preventing heart failureVol.27:Keeping cells in shape to fight sepsis